Prevention of Reperfusion Injury in Myocardial Infarction II - PRIME II
Effect of Paracetamol on Reperfusion Injury in Patients with ST-Elevation Myocardial Infarction: A Multi-centre, Open-Label, Randomised Control Trial.
Te Whatu Ora
75 participants
Mar 2, 2026
Interventional
Conditions
Summary
The PRIME II trial aims to show that giving Paracetamol to patients who present with STEMI reduces their total infarction size. The reduction will be produced by reducing the amount of reperfusion injury that occurs after the culprit artery is opened. If this trial is positive there would be a change to standard care of myocardial infarction, as well as further research into the exact mechanism of Paracetamol’s cardioprotective effect. This could lead to specific agents being produced to specifically target this mechanism of action.
Eligibility
Inclusion Criteria1
- Patients presenting to Waikato and Christchurch Hospitals Emergency Departments with Acute STEMI.
Exclusion Criteria3
- Allergy to Paracetamol
- Known liver failure (Child-Pugh class C)
- Glasgow Coma Scale less than 15
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1.5g of Paracetamol, alongside current standard ST-elevation Myocardial Infarction (STEMI) treatment - dual anti-platelet therapy, analgesia, enoxaparin. Patients who have already taken Paracetamol within four hours of diagnosis of STEMI will be given an extra dose of 500mg, if they took 1g, and then be included in the study. Patients will then be given 1g of Paracetamol four times per day, for 2 days post Percutaneous Coronary Intervention, as well as their standard therapy as directed by their Cardiologist. This adherence will be monitored by auditing medication charts.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12626000027314